top of page

Founder Bankers: Why Nelson Advisors Leads Europe's Lower to Mid-Market HealthTech, MedTech and Health AI M&A

Writer: Nelson Advisors
Nelson Advisors
2 minutes ago
12 min read
Founder Bankers: Why Nelson Advisors Leads Europe's Lower to Mid-Market HealthTech, MedTech and Health AI M&A
Founder Bankers: Why Nelson Advisors Leads Europe's Lower to Mid-Market HealthTech, MedTech and Health AI M&A


Selling a healthcare technology company is the most consequential transaction most founders will ever make. It is also, for most of them, the first. Years of product decisions, regulatory submissions, hospital pilots and difficult funding rounds are compressed into a process that lasts a few months and is decided by a handful of conversations.


In that process the founder is usually the least experienced person in the room. The acquirer's corporate development team has done this many times. The private equity sponsor does it for a living. The lawyers on both sides have a precedent for every clause. The founder has one company, one outcome and no second attempt.


That imbalance is why the choice of adviser matters so much. Yet the traditional model of investment banking was never designed for this client. It was built around large corporates and large fees, and it is staffed by career financiers who have advised on many businesses and built none.


Nelson Advisors was founded to offer something different. We are a London-based boutique dedicated exclusively to mergers, acquisitions, partnerships and investments across HealthTech, MedTech, Digital Health, Healthcare IT and Health AI. We focus on the lower to mid market, broadly $25M to $250M in enterprise value. And we are led by people who have founded, scaled and sold healthcare technology companies themselves.


We call that model the founder banker. This article explains what the term means, why it produces better outcomes for founders and shareholders, and why we believe the combination of founder experience and single-sector focus has made Nelson Advisors Europe's leading adviser in this part of the market.


What we mean by 'founder bankers'


A founder banker is an M&A adviser who has been a founder first. The phrase describes a career path as much as a service. The conventional banker moves in a straight line from analyst to managing director, learning how transactions work from the adviser's side of the table. The founder banker has started a company, raised money for it, hired and fired, missed a quarter, won a contract that saved the business, and eventually sold it. Only then did they start advising others.


Both of our founding partners fit that description.


Lloyd Price spent more than a decade in consumer internet, in senior roles at Kelkoo, Yahoo! UK & Europe and Badoo, before co-founding Zesty in 2012. Zesty built a digital patient engagement and appointment booking platform, raised more than $20 million of venture capital and sold into the NHS, one of the hardest healthcare buyers in the world to sell to. In May 2020 it was acquired by Induction Healthcare Group, then listed on AIM. He went on to run Hive Health as chief executive.


Paul Hemings combines both sides of the term. He was an investment banker at Credit Suisse and later worked in strategy and investment at Invesco, then co-founded and exited Neutrally, a metabolic health company. He has structured transactions for large institutions and has also been the founder waiting for the term sheet.


The label matters because of what those experiences teach. A founder who has sold a company knows what an earn-out feels like eighteen months after completion, when the acquirer's priorities have changed. They know how diligence drains a leadership team that still has a business to run. They know which promises made during courtship tend to survive integration and which do not.


None of that appears in a financial model. All of it affects the value a founder finally receives. Our view is simple: the best person to guide a healthcare technology founder through an exit is someone who has been through one.


Why the founder perspective changes the outcome


Founder experience is not a branding exercise. It changes the work in four practical ways.


We translate between operators and buyers. Acquirers pay for what they can understand and underwrite. A founder describes the business in terms of product, clinicians and patients. A buyer wants recurring revenue quality, retention, gross margin and regulatory risk. Having run healthcare technology companies, we can read a product roadmap and a data room with equal fluency and turn one into the other. That is the difference between an information memorandum that lists features and one that explains why the asset is hard to replicate.


We know where deals break. In our sector they rarely break on headline price. They break on a lapsed technical file, an unclear data licence, a customer contract with a change-of-control clause, or an NHS framework that cannot be novated. Operators know where these problems hide because they have created and fixed them. We look for them before a buyer does, when they can still be resolved rather than priced in.


We negotiate structure, not just valuation. In the lower to mid market the headline number is only part of the outcome. Deferred consideration, earn-out metrics, rollover equity, warranties and the founder's role after completion often decide what shareholders actually receive. When a private equity platform is the buyer, founders typically roll 20% to 40% of their equity into the new group. Advising on that decision requires an honest view of the platform's plan, and we have sat on the receiving end of such plans.


We understand the personal side. An exit is a financial event and a personal one. Founders worry about their team, their product and their own next chapter, often while investors with different time horizons are pressing for a result. Valuation expectations set in 2021 have had to be reset in many boardrooms since. A career financier can manage a process. A former founder can also tell a client, credibly, what the other side of the deal is like.


We sometimes describe this as operational empathy. In practice it means advice that is candid, specific and grounded in having done the job.


The niche: the lower to mid market and nothing but healthcare technology


Our focus is narrow by design. We advise healthcare technology companies with an enterprise value of roughly $25M to $250M, with selected mandates above that. The typical client has $5M to $50M of revenue, $1M to $10M of EBITDA or a credible path to it, and between 20 and 250 employees. Its product has cleared the regulatory and procurement hurdles that stop most start-ups.


This is where most European healthcare technology value is realised. Europe produces few listed healthtech companies and few multi-billion exits. It produces a large number of well-built, clinically validated businesses that become valuable to a strategic acquirer or a private equity platform at this scale.


Our own analysis puts the average European healthtech transaction at about $13.6M in early 2022 and about $46.6M in early 2026, a more than threefold increase. The centre of gravity has moved into our band.

It is also a segment that the advisory market has served poorly, for three reasons.


  1. Bulge-bracket banks cannot make the economics work. Their fee thresholds and cost bases are set for transactions many times larger. A $60M trade sale is staffed by juniors, if it is taken on at all.


  2. Generalist boutiques and accounting firms lack the domain depth. A team that sold a logistics business last month and a software reseller the month before will struggle to explain why a Class IIb certificate, a DiGA listing or an integration with a hospital's electronic patient record is worth paying for.


  3. Companies at this size are complicated. They often combine venture investors, angel shareholders, founder control and incomplete financial reporting. They need more preparation, not less, than a large corporate carve-out.


The result is a gap between the importance of these transactions to their shareholders and the quality of advice usually available to them. Sector focus closes that gap. Because we work only in healthcare technology, every conversation with a buyer, every valuation and every diligence question adds to knowledge that the next client benefits from. A generalist starts each mandate by learning the sector. We start by knowing who is buying, what they paid last time and what they are short of.


Three sectors, one specialism


HealthTech, MedTech and Health AI are often grouped together, but buyers value them differently. Advising across all three, and only these three, lets us position each company against the right comparables.


HealthTech. This covers digital health, healthcare IT and software sold to providers, payers, pharma and consumers: patient engagement, electronic records, workflow, virtual care, revenue cycle and interoperability. Buyers look first at the quality of recurring revenue. Contract length, net revenue retention, depth of integration into clinical systems and the cost of switching all matter more than growth alone. Platforms that sit in the daily workflow of a hospital are worth far more than applications a customer could turn off.


MedTech. Devices, diagnostics and connected hardware are valued on regulatory status, clinical evidence, reimbursement and manufacturing margin. A completed MDR or IVDR certification is now an asset in its own right, because many competitors have not achieved it. Acquirers also want to see a software and data layer around the device, which turns a one-off product sale into a recurring relationship.


Health AI. Clinical and operational AI attracts the highest multiples and the hardest questions. Buyers want to know what data the model was trained on and whether the company has the right to use it. They ask how the model performs in real clinical settings, how it is regulated as a medical device, and whether it meets the EU AI Act's requirements. They also ask whether a general-purpose foundation model could replicate the product. Companies with proprietary data and explainable, validated models earn a premium. Thin wrappers do not.


We use a simple framework to make this concrete: App > Platform > Data > AI. It sorts a company's assets into four layers and shows where its defensibility, and therefore its valuation, really sits.


Indicative enterprise value to revenue ranges for 2026, from our lower mid-market analysis, show how wide the spread is:


Category

EV / revenue

AI-native clinical and diagnostic software

6.0x to 8.0x+

Data and interoperability infrastructure

5.5x to 7.0x

Value-based care platforms

5.5x to 7.0x

General healthtech SaaS

4.0x to 6.0x

MDR-ready medtech hardware

3.5x to 5.0x

Revenue cycle and back-office health IT

3.5x to 5.0x

Unprofitable early-stage digital health

3.0x to 4.0x

The same company can sit in more than one row depending on how it is presented. Deciding which story the evidence supports, and telling it to the buyers who will pay for it, is a large part of what a specialist adviser is for.


Why this matters now: the European market in 2026


The case for specialist advice is stronger today than at any point in the past five years, because the market has become more selective.


Fewer, larger, more demanding deals. European healthcare M&A value rose about 87% to €31.8 billion in the first half of 2025, while the number of deals fell about 8%, from 454 to 418. That pattern has continued. Buyers are writing bigger cheques for fewer companies and doing more diligence before they sign. A company that is well prepared attracts competition. One that is not may attract no bids at all.


Capital is concentrating in AI. AI-enabled companies captured around 55% of healthtech funding heading into 2026. For founders outside that group, venture funding for the next round is harder to find, and a sale or merger is often the better route to scale. For founders inside it, the question is whether to sell at a premium now or raise and risk commoditisation later.


Regulation is sorting the market. The Medical Device Regulation and In Vitro Diagnostic Regulation, the EU AI Act and the European Health Data Space each impose costs that smaller companies struggle to carry alone. We have called this regulatory Darwinism. Companies that have done the work command a premium. Those that have not become acquisition targets, sometimes distressed ones. National regimes add further layers, from NHS digital assurance standards in the UK to DiGA reimbursement in Germany.


The buyer universe has changed. Three groups now account for most activity in our band: private equity-backed platforms making add-on acquisitions, mid-cap strategics filling product gaps, and North American acquirers looking for a European foothold. Each values a target differently and runs a different process. Buy-and-build has become the central private equity strategy in European healthtech, which means many founders will sell to a platform rather than to a traditional trade buyer.


Europe adds its own complexity. It is not one healthcare market but many, each with its own payers, procurement rules, languages and reimbursement codes. A buyer in Boston or Munich needs help understanding why a contract base in the NHS or the Nordic regions is valuable and transferable. A founder needs an adviser who can explain it.


How we work


We advise on mergers, acquisitions, partnerships and investments. That includes sell-side mandates for founders and shareholders, buy-side work for strategics and private equity platforms, and board-level advice on strategic options. Four features define the approach.


Strategy before process. Not every company should be sold, and not every company should be sold now. We begin most engagements with our Build, Buy, Partner, Sell framework. It tests whether the board's objectives are best met by organic growth, by acquiring, by a commercial partnership or by an exit. Sometimes the right answer is to spend twelve months fixing a regulatory gap or a revenue concentration before going to market. We would rather say so than run a process that fails.


Preparation as the main lever on value. Most of the value in a sale is created before the first buyer is contacted. We work with management on the equity story, the financial presentation, the regulatory and data position and the likely diligence questions. As former operators we know what a clean technical file and a credible forecast look like, and we know how long they take to produce.


Targeted buyer access. In our market the right acquirers for a given company usually number in the dozens, not the hundreds. We favour focused, often bilateral or limited processes over broad auctions. They protect confidentiality, keep management time under control and let us build real competitive tension among buyers with a strategic reason to pay. Our relationships with corporate development teams, private equity sponsors and their portfolio platforms across the UK, Western Europe and North America are refreshed every week by live mandates.


Senior attention throughout. Partners lead every engagement from first meeting to completion. A founder who appoints us works with founders, not with a team that changes once the mandate is signed.


Behind this sits a research effort that is unusual for a firm of our size. We publish analysis on valuations, buyers, regulation and sub-sector trends at Healthcare.Digital, along with a weekly newsletter read by more than 5,000 subscribers. Lloyd is also Health Executive in Residence at UCL Global Business School for Health and co-founded the Digital Healthcare Council. That work is not marketing for its own sake. It keeps us close to the founders, investors and acquirers who make up the market, and it means clients get advice based on current data.


Five questions to ask any M&A advisor


Founders choosing an adviser should test every firm, including ours, against the same questions.


  1. Have you built and sold a company yourself? Experience of advising on exits is not the same as experience of going through one. Ask what the adviser learned from their own.


  2. How much of your work is in my sector? An adviser who works only in healthcare technology will know the buyers, the regulatory issues and the recent pricing. One who covers it occasionally will be learning at your expense.


  3. Is my deal the right size for you? A transaction that is small for a large bank will receive junior attention. A firm built for the lower to mid market treats it as core business.


  4. Who will actually do the work? Ask to meet the people who will prepare the materials, call the buyers and sit in the negotiation. They should be the people who pitched.


  5. Will you tell me not to sell? The most valuable advice is sometimes to wait, to fix something first, or to choose a partnership over a sale. An adviser who only earns when a deal completes needs the integrity to say so.


We built Nelson Advisors to answer each of these well.


Founders advising founders


European healthcare technology has matured. The companies are better, the buyers are more sophisticated and the regulation is tougher. The advice available to founders has to rise to the same standard.


The founder banker model is our answer. It combines the discipline of investment banking with the judgement that only comes from building and selling a company. Applied to a single sector and a single part of the market, it gives founders an adviser who understands their product, their buyers and their position, and who has stood where they stand.


That is the niche we have chosen and the reason we believe Nelson Advisors leads it: healthtech entrepreneurs advising healthtech entrepreneurs, in the part of the European market where most value is realised.


If you are a founder, chief executive, board member or investor in a HealthTech, MedTech or Health AI company and are considering a sale, an acquisition, a partnership or an investment in the next two years, we would be glad to talk. An early conversation costs nothing, and the best outcomes begin with preparation long before a process starts.


Nelson Advisors > European Healthcare Technology Investment Banking


Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk


Healthcare.Digital is the Google News approved HealthTech and MedTech Thought Leadership platform for Nelson Advisors, positioning them as a specialised authority on European Healthcare Technology M&A and strategic corporate development. https://www.healthcare.digital 


Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb 



Nelson Advisors LLP


Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT




Meet Nelson Advisors @ Events in 2026


Digital Health Rewired > March 2026 > Birmingham, UK  


NHS ConfedExpo  > June 2026 > Manchester, UK 


HLTH Europe > June 2026, Amsterdam, Netherlands


HIMSS AI in Healthcare > July 2026, New York, USA


Bits & Pretzels > September 2026, Munich, Germany  


HealthInvestor Healthcare Summit > September 2026, London, UK 


World Health Summit 2026 > October 2026, Berlin, Germany


HLTH USA 2026 > October 2026, USA


Global Health Exhibition 2026 > October 2026, Riyadh, Saudi Arabia


Web Summit 2026 > November 2026, Lisbon, Portugal  


MEDICA 2026 > November 2026, Düsseldorf, Germany


Leaders in Health Summit 2026 > November 2026, London, UK 


Venture Capital World Summit > December 2026, Toronto, Canada


Meet Nelson Advisors @ Events in 2027


Digital Health Rewired > March 2027 > Birmingham, UK


Barclays Health Elevate > March 2027, London, UK 


NHS ConfedExpo  > June 2027 > Manchester, UK 


HLTH Europe > June 2027, Amsterdam, Netherlands


Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk
Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk



Comments


Commenting on this post isn't available anymore. Contact the site owner for more info.
bottom of page